# CARMEN-LC03 (NCT04154956)

> SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04154956
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Sanofi
- Conditions: Non-small Cell Lung Cancer Metastatic
- Interventions: SAR408701; Docetaxel
- Enrollment: 389
- Primary outcome: Progression-free Survival (PFS)
- Primary outcome: Overall Survival (OS)

## Commentary we found

- X threads: 8
- YouTube: 5
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=carmen-lc03-nct04154956

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04154956", "email": "<work email>"}; the inbox owner confirms by the emailed link.